Value
4.4/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 5.6 |
| EV/EBITDA | 0.0 |
| p ocf | 4.6 |
| Analyst target | 5.0 |
- ▸P/OCF: 24.5x (FFO proxy — REITs gated off P/E)
VTR · Why this verdict
Why Ventas (VTR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Ventas is a healthcare REIT growing revenue at 22% annually with 570% free cash flow conversion relative to net income, but the stock offers only 4.4% upside to analyst targets, carries a below-average business quality score of 4.2, and has a dividend flagged as potentially yield-trap territory — limiting the near-term appeal despite solid operating momentum.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The dividend is flagged as a yield trap with potentially unsafe coverage, while the dividend safety score is only 3.5/10 — suggesting the high dividend yield may not be sustainably funded from current earnings and could be cut if property income or tenant credit quality deteriorates. Catalyst breakdown | Dividend coverage should improve over 12 months as operating income grows, with free cash flow per share rising above 150% of the dividend per share to remove the yield trap designation. | →Stable |
| CounterThe 570% FCF-to-net-income ratio suggests cash is being generated well in excess of GAAP earnings; if much of that FCF is available for dividends, the yield trap designation may be overly conservative based on accounting metrics that understate real cash. | ||
Ventas generates free cash flow at 570% of net income — an extraordinary ratio for a REIT that reflects the gap between depreciation-heavy GAAP earnings and actual cash generation — making the accounting quality score much stronger than GAAP metrics suggest. Quality breakdown | Free cash flow conversion should remain above 300% of net income over the next 12 months, confirming that the underlying cash generation is structural and not a one-period timing event. | →Stable |
| CounterA 570% FCF-to-net-income ratio in a REIT may reflect asset sales or one-time working capital benefits rather than recurring cash generation; if this normalizes, the apparent financial strength is overstated. | ||
Revenue is growing at 22% year-over-year — the highest growth rate among healthcare REIT peers, placing Ventas in the top position on the peer rank growth dimension — driven by senior housing and life science real estate demand from aging demographics. Peer-rank breakdown | Revenue growth should remain above 15% annually over the next 12 months, maintaining the industry growth leader position and supporting the case for a premium multiple relative to peers. | →Stable |
| CounterHigh revenue growth in a REIT can reflect new property acquisitions funded by debt rather than same-store organic growth; leverage-funded growth is not sustainable indefinitely and may eventually compress returns. | ||
With only 4.4% upside to the analyst target of $87.12 from the current $83.46 and a risk-reward ratio of 0.75, the entry case is weak despite positive fundamentals — the stock needs to pull back toward $78-79 to establish a favorable asymmetry before adding to positions. Bear case | A pullback toward $79 (below the current price of $83.46 by more than 5%) should create a favorable entry with 10% upside to the analyst target, improving the risk-reward above 1.0. | →Stable |
| CounterIf fundamental momentum (22% revenue growth, improving RSI from oversold levels at 39, and 570% FCF conversion) continues to attract institutional buyers, the stock may never pull back to a more attractive entry, and waiting for a lower price means missing the thesis. | ||
The dividend is flagged as a yield trap with potentially unsafe coverage, while the dividend safety score is only 3.5/10 — suggesting the high dividend yield may not be sustainably funded from current earnings and could be cut if property income or tenant credit quality deteriorates.
→StableCatalyst breakdown
- Expectation
- Dividend coverage should improve over 12 months as operating income grows, with free cash flow per share rising above 150% of the dividend per share to remove the yield trap designation.
CounterThe 570% FCF-to-net-income ratio suggests cash is being generated well in excess of GAAP earnings; if much of that FCF is available for dividends, the yield trap designation may be overly conservative based on accounting metrics that understate real cash.
Ventas generates free cash flow at 570% of net income — an extraordinary ratio for a REIT that reflects the gap between depreciation-heavy GAAP earnings and actual cash generation — making the accounting quality score much stronger than GAAP metrics suggest.
→StableQuality breakdown
- Expectation
- Free cash flow conversion should remain above 300% of net income over the next 12 months, confirming that the underlying cash generation is structural and not a one-period timing event.
CounterA 570% FCF-to-net-income ratio in a REIT may reflect asset sales or one-time working capital benefits rather than recurring cash generation; if this normalizes, the apparent financial strength is overstated.
Revenue is growing at 22% year-over-year — the highest growth rate among healthcare REIT peers, placing Ventas in the top position on the peer rank growth dimension — driven by senior housing and life science real estate demand from aging demographics.
→StablePeer-rank breakdown
- Expectation
- Revenue growth should remain above 15% annually over the next 12 months, maintaining the industry growth leader position and supporting the case for a premium multiple relative to peers.
CounterHigh revenue growth in a REIT can reflect new property acquisitions funded by debt rather than same-store organic growth; leverage-funded growth is not sustainable indefinitely and may eventually compress returns.
With only 4.4% upside to the analyst target of $87.12 from the current $83.46 and a risk-reward ratio of 0.75, the entry case is weak despite positive fundamentals — the stock needs to pull back toward $78-79 to establish a favorable asymmetry before adding to positions.
→StableBear case
- Expectation
- A pullback toward $79 (below the current price of $83.46 by more than 5%) should create a favorable entry with 10% upside to the analyst target, improving the risk-reward above 1.0.
CounterIf fundamental momentum (22% revenue growth, improving RSI from oversold levels at 39, and 570% FCF conversion) continues to attract institutional buyers, the stock may never pull back to a more attractive entry, and waiting for a lower price means missing the thesis.
Per-dimension breakdown
Quality
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.7 |
| ROA | 1.5 |
| Gross margin | 4.1 |
| Op margin | 5.5 |
| Net margin | 2.1 |
| Current ratio | 0.8 |
| FCF quality | 10.0 |
| Moat | 5.6 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 570% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
6.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 8.0 |
| EPS growth | 4.0 |
- ▸Strong growth: 22% YoY
Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 4.0 |
| Analyst rating | 7.5 |
| Price target | 6.7 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider buying — $93,110 (0.000% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.9 |
| quality rank | 2.7 |
| growth rank | 8.5 |
- ▸Industry growth leader
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.2 |
| support resistance | 1.8 |
| 52w position | 9.0 |
Risk (lower is worse)
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.3 |
| days to cover | 6.0 |
| volatility | 6.1 |
| put call | 10.0 |
| implied vol | 7.7 |
| beta | 8.6 |
| debt equity | 5.4 |
| news risk | 5.5 |
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 3.5 |
| news activity | 5.0 |
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- MOMENTUM:6.8>=5.5
- INSIDER:OK
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.1<1.5@spot
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.08
Upside
+0.8%
Downside
9.8%
Sizing output
AVOID
SetupBREAKOUT — Golden cross, above all MAs, RSI 68, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Risk (lower is worse) at 7.1) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:0.1<1.5@spot) reinforce the read. Current asymmetry R:R is 0.08 — supplementary context, not the trigger for this path.
The strongest dimensions are Risk (lower is worse) at 7.1, Momentum at 6.8, and Catalyst at 6.4; the weakest are Technical at 4.0, Quality at 4.2, and Value at 4.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.08 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Ventas generates free cash flow at 570% of net income — an extraordinary ratio for a REIT that reflects the gap between depreciation-heavy GAAP earnings and actual cash generation — making the accounting quality score much stronger than GAAP metrics suggest.
Trip ifFree cash flow conversion falls below 150% of net income for 2 consecutive quarters, indicating the exceptional conversion ratio has normalized away.
- P2Revenue is growing at 22% year-over-year — the highest growth rate among healthcare REIT peers, placing Ventas in the top position on the peer rank growth dimension — driven by senior housing and life science real estate demand from aging demographics.
Trip ifRevenue growth falls below 10% year-over-year for 2 consecutive quarters, indicating the industry growth leader position is not being maintained.
- P3With only 4.4% upside to the analyst target of $87.12 from the current $83.46 and a risk-reward ratio of 0.75, the entry case is weak despite positive fundamentals — the stock needs to pull back toward $78-79 to establish a favorable asymmetry before adding to positions.
Trip ifAnalyst consensus price target falls below $78, more than 6% below the current price of $83.46, indicating the target has been cut below current trading levels.
- P4The dividend is flagged as a yield trap with potentially unsafe coverage, while the dividend safety score is only 3.5/10 — suggesting the high dividend yield may not be sustainably funded from current earnings and could be cut if property income or tenant credit quality deteriorates.
Trip ifDividend is cut by more than 20% below the current level, confirming the yield trap warning has materialized.